Wellington Management Group Portfolio holdings
Wellington Management Group, founded in 1928 by Walter L. Morgan and headquartered in Boston, Massachusetts, is one of the world’s largest independent asset management firms, overseeing trillions in assets for a diverse client base including pension funds, endowments, and mutual fund investors. Renowned for its active management approach, Wellington offers a broad range of investment strategies across equities, fixed income, multi-asset, and alternative investments, emphasizing deep research and long-term partnerships with clients. The firm gained early fame for launching the Wellington Fund, one of the first balanced mutual funds, and has since maintained a reputation for disciplined, collaborative portfolio management. With a global presence and a focus on customized solutions, Wellington remains a trusted name in institutional and retail investing.
Top Buys
| 1 |
Exxon Mobil
XOM
|
$2.48B |
| 2 |
Wells Fargo
WFC
|
$2.4B |
| 3 |
NVIDIA
NVDA
|
$2.03B |
| 4 |
American Express
AXP
|
$948M |
| 5 |
Amazon
AMZN
|
$855M |
Top Sells
| 1 |
Pfizer
PFE
|
$1.71B |
| 2 |
Chubb
CB
|
$1.57B |
| 3 |
ConocoPhillips
COP
|
$1.49B |
| 4 |
Microsoft
MSFT
|
$1.37B |
| 5 |
Advanced Micro Devices
AMD
|
$1.15B |
Sector Composition
| 1 | Technology | 21.08% |
| 2 | Healthcare | 20.37% |
| 3 | Financials | 14.37% |
| 4 | Consumer Discretionary | 9.44% |
| 5 | Industrials | 9.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1601
GameStop
GME
$10.1B
| $929K | ﹤0.01% |
74,185
-2,912
| -4% | -$36.5K |
|
1602
Ligand Pharmaceuticals
LGND
$3.25B
| $917K | ﹤0.01% |
12,548
-2,139
| -15% | -$156K |
|
1603
MeiraGTx Holdings
MGTX
$619M
| $910K | ﹤0.01% |
149,961
+3,505
| +2% | +$21.3K |
|
|
SWN
1604
DELISTED
Southwestern Energy Company
SWN
| $908K | ﹤0.01% |
119,835
-665,114
| -85% | -$5.04M |
|
1605
Puma Biotechnology
PBYI
$253M
| $905K | ﹤0.01% |
+170,765
| New | +$905K |
|
1606
Arvinas
ARVN
$575M
| $896K | ﹤0.01% |
21,702
-6,903
| -24% | -$285K |
|
1607
Zebra Technologies
ZBRA
$16B
| $887K | ﹤0.01% |
2,942
-208,441
| -99% | -$62.8M |
|
1608
Arrow Electronics
ARW
$6.57B
| $886K | ﹤0.01% |
6,841
+4,463
| +188% | +$578K |
|
1609
Unum
UNM
$12.6B
| $884K | ﹤0.01% |
16,468
+2,964
| +22% | +$159K |
|
1610
Xeris Biopharma Holdings
XERS
$1.27B
| $877K | ﹤0.01% |
+396,945
| New | +$877K |
|
1611
Gen Digital
GEN
$18.2B
| $873K | ﹤0.01% |
38,989
+29,940
| +331% | +$671K |
|
1612
Viatris
VTRS
$12.2B
| $865K | ﹤0.01% |
72,478
-4,549
| -6% | -$54.3K |
|
1613
Design Therapeutics
DSGN
$367M
| $864K | ﹤0.01% |
+214,310
| New | +$864K |
|
|
ANSS
1614
DELISTED
Ansys
ANSS
| $861K | ﹤0.01% |
2,480
-1,282,035
| -100% | -$445M |
|
|
GRTS
1615
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $851K | ﹤0.01% |
+331,079
| New | +$851K |
|
1616
Monte Rosa Therapeutics
GLUE
$305M
| $851K | ﹤0.01% |
+120,647
| New | +$851K |
|
|
BLUE
1617
DELISTED
bluebird bio
BLUE
| $845K | ﹤0.01% |
33,019
+2,337
| +8% | +$59.8K |
|
1618
Black Diamond Therapeutics
BDTX
$167M
| $840K | ﹤0.01% |
+165,686
| New | +$840K |
|
1619
Ironwood Pharmaceuticals
IRWD
$188M
| $828K | ﹤0.01% |
95,094
-2,324
| -2% | -$20.2K |
|
1620
Erie Indemnity
ERIE
$17.5B
| $820K | ﹤0.01% |
2,041
+136
| +7% | +$54.6K |
|
1621
Harmony Biosciences
HRMY
$2.07B
| $819K | ﹤0.01% |
24,401
-15,035
| -38% | -$505K |
|
1622
Absci
ABSI
$368M
| $817K | ﹤0.01% |
+143,810
| New | +$817K |
|
1623
Coherus Oncology, Inc. Common Stock
CHRS
$150M
| $815K | ﹤0.01% |
+341,202
| New | +$815K |
|
1624
Ecopetrol
EC
$18.7B
| $815K | ﹤0.01% |
68,805
+28,934
| +73% | +$343K |
|
1625
UiPath
PATH
$6.15B
| $804K | ﹤0.01% |
35,469
-9,593
| -21% | -$217K |
|